Omalizumab在红肉过敏患者中的应用观察
Omalizumab Linked With Anaphylaxis Elimination in Meat Allergy
一项观察性研究表明,Omalizumab治疗可显著减少红肉过敏患者的过敏反应,53%的患者在使用前需要肾上腺素,而使用后无一例需要。大部分患者报告了反应频率和严重程度的改善,33%的患者能够部分重新引入肉类饮食。然而,研究未设对照组,且存在选择偏倚,需进一步研究确认其长期效果。
— Observational study supports benefit of anti-IgE antibody against alpha-gal syndrome
November 15, 2026 • 4 min read
For patients with alpha-gal syndrome who had severe allergic reactions to red meat despite avoidance, treatment with omalizumab (Xolair) appeared to eliminate anaphylaxis risk in one case series.
Whereas 53% of 64 such patients studied had required epinephrine for a presumed alpha-gal reaction before starting omalizumab, none did while taking the biologic, reported Collette M. Tilly, MD, of the University of North Carolina at Chapel Hill, at the American College of Allergy, Asthma & Immunology (ACAAI) annual meeting.
All but a few of the patients (95%) reported meaningful improvement in reaction frequency or severity as well, with 33% able to at least partially reintroduce meat into their diet.
"We're definitely encouraged by the results," Tilly told MedPage Today. "Omalizumab is not a cure for alpha-gal syndrome, nor should it be considered [as] putting these patients into remission. But it could reduce reaction frequency and severity, decrease the need for epinephrine, and then potentially even lessen the fear of unexpected reactions. And that would hopefully translate into meaningful improvement in quality of life for these patients."
Omalizumab reduces circulating immunoglobulin E (IgE) available to trigger mast cells that lead to allergic reactions across IgE triggers. Because it's mechanism is not allergen-specific, the antibody is approved to treat IgE-mediated food allergy broadly and has shown induction of tolerance on par with oral immunotherapy.
Alpha-gal syndrome is an IgE-mediated hypersensitivity to galactose-α-1,3-galactose (alpha-gal) found in beef, pork, lamb, and other meats from mammals as well as animal byproducts such as gelatin. The condition most commonly occurs after tick bites.
"[T]he rationale that specific-IgE is responsible for the reaction and that omalizumab reduces free, and ultimately mast cell bound, IgE provides a logical basis for benefit," Dennis K. Ledford, MD, of the University of South Florida in Tampa, had written earlier this year when a smaller series from the group was reported. "The dose of omalizumab is important, and the treatment does not guarantee ad lib ingestion without adverse events," he added.
Alpha-gal syndrome wasn't included in the randomized trials demonstrating benefit of omalizumab in food allergy. "Milk, egg, peanut, cashew, walnut -- they studied all these foods and that wasn't one of them, obviously," commented Jay Lieberman, MD, of the University of Tennessee Health Science Center in Memphis. "But I would still consider that on-label, if you consider alpha-gal a food allergy."
However, alpha-gal syndrome is less predictable than other food allergies, he cautioned. "If you have a peanut allergy, you will react if I perform a challenge; with alpha-gal, it depends on so many things ... It depends on co-factors more often than other food allergies. It depends on the fat content of the food, how much they eat," he said. So a key question is how much meat is allowed to be eaten while on omalizumab, if at all, since the product label notes its use in the context of avoidance, he added.
Use in alpha-gal syndrome has been spreading, although anaphylaxis has been reported in at least one case on patient social media networks. A study of those reported acknowledged potential risk: "Due to omalizumab manufactured in Chinese Hamster Ovary cells, which may variably glycosylate with alpha-gal, the risk of anaphylaxis could be higher."
Tilly's group examined a retrospective, single-center cohort of 64 patients with confirmed alpha-gal syndrome who were treated for at least 3 months with omalizumab from April 2022 through November 2025 and who had at least 3 months of follow-up. The median treatment duration was 23 months, with some patients on the medication for up to 83 months.
Their mean age was 55, and 56% were female. Tilly noted that the cohort was a clinically high-risk population, not a mild, well-controlled one. Among the patients, 81% had documented anaphylaxis reactions to alpha-gal at baseline, and 53% had required epinephrine (34 of 64) before starting omalizumab.
While on omalizumab, 13 of the patients (20%) reported partial reintroduction of mammalian products and eight (13%) had full reintroduction, although physicians continued to recommend avoidance in line with the labeled indications, Tilly said.
Adverse events (AE) while on omalizumab were uncommon, mostly arthralgias, although two patients (3%) discontinued the biologic due to an AE.
Tilly cautioned that the findings could not attribute causation due to lack of an untreated comparator group or prospective outcome assessment. "Symptoms and allergen sensitivity may change over time independent of treatment," she acknowledged.
The study was further limited by potential selection and referral bias as well as the heterogeneous dosing of omalizumab and follow-up duration. Exposure frequency and dose were also not standardized during treatment.
Prospective, multicenter studies are now needed to confirm a treatment effect and to define optimal dosing, treatment duration, and criteria for omalizumab discontinuation, Tilly said.
来源:MedPage Today · medpagetoday.com